Pilot Study of Hyperpolarized $^{13}$C Metabolic Imaging in Pediatric Patients with Diffuse Intrinsic Pontine Glioma and Other CNS Cancers


*AJNR Am J Neuroradiol* 2021, 42 (1) 178-184
doi: https://doi.org/10.3174/ajnr.A6937
http://www.ajnr.org/content/42/1/178
Pediatric brain tumors are the most commonly encountered solid tumors in childhood and now contribute to most cancer-related deaths in children. Among these tumors, diffuse intrinsic pontine glioma (DIPG) poses the gravest threat, with the median overall survival in children being only 9 months from diagnosis, despite exhaustive research efforts. In managing pediatric brain tumors, a key issue facing the neuro-oncology community is the lack of imaging biomarkers that can support definitive and rapid assessment of response or resistance to treatment. While treatment response has traditionally been evaluated through MR imaging, there remain considerable challenges to radiographic interpretations of disease status. These potential shortcomings are exacerbated in the setting of novel therapies, such as immunotherapy, where there are no current standards to determine treatment effect versus disease progression based on imaging alone.

Because of the challenges in monitoring pediatric brain tumors using standard MR imaging, hyperpolarized carbon-13 (HP-13C) MR imaging presents a promising molecular methodology that

Original Research

Pilot Study of Hyperpolarized $^{13}$C Metabolic Imaging in Pediatric Patients with Diffuse Intrinsic Pontine Glioma and Other CNS Cancers


ABSTRACT

BACKGROUND AND PURPOSE: Pediatric CNS tumors commonly present challenges for radiographic interpretation on conventional MR imaging. This study sought to investigate the safety and tolerability of hyperpolarized carbon-13 (HP-$^{13}$C) metabolic imaging in pediatric patients with brain tumors.

MATERIALS AND METHODS: Pediatric patients 3 to 18 years of age who were previously diagnosed with a brain tumor and could undergo MR imaging without sedation were eligible to enroll in this safety study of HP-$^{13}$C pyruvate. Participants received a one-time injection of HP-$^{13}$C pyruvate and were imaged using dynamic HP-$^{13}$C MR imaging. We assessed 2 dose levels: 0.34 mL/kg and the highest tolerated adult dose of 0.43 mL/kg. Participants were monitored throughout imaging and for 60 minutes postinjection, including pre- and postinjection electrocardiograms and vital sign measurements.

RESULTS: Between February 2017 and July 2019, ten participants (9 males; median age, 14 years; range, 10–17 years) were enrolled, of whom 6 completed injection of HP-$^{13}$C pyruvate and dynamic HP-$^{13}$C MR imaging. Four participants failed to undergo HP-$^{13}$C MR imaging due to technical failures related to generating HP-$^{13}$C pyruvate or MR imaging operability. HP-$^{13}$C pyruvate was well-tolerated in all participants who completed the study, with no dose-limiting toxicities or adverse events observed at either 0.34 (n = 3) or 0.43 (n = 3) mL/kg. HP-$^{13}$C pyruvate demonstrated characteristic conversion to $^{13}$C lactate and $^{13}$C bicarbonate in the brain. Due to poor accrual, the study was closed after only 3 participants were enrolled at the highest dose level.

CONCLUSIONS: Dynamic HP-$^{13}$C MR imaging was safely performed in 6 pediatric patients with CNS tumors and demonstrated HP-$^{13}$C pyruvate brain metabolism.

ABBREVIATIONS: aSNR = apparent total SNR; EPSI = echo-planar spectroscopic imaging; DIPG = diffuse intrinsic pontine glioma; HP-$^{13}$C = hyperpolarized carbon-13
can potentially extend current imaging capabilities. HP-[13C] MR imaging has enabled the noninvasive investigation of in vivo brain metabolism using molecular probes whose signal is transiently enhanced via dynamic nuclear polarization. In studies of the adult brain, intravenously injected HP-[1-13C]pyruvate was shown to safely transport across the BBB and undergo enzymatic conversion to downstream metabolites [1-13C]lactate and [13C]bicarbonate, which serve as respective markers of glycolysis and oxidative phosphorylation. Given the metabolic alterations associated with cancer, several of these imaging studies were designed to demonstrate the feasibility of HP-[13C] MR imaging in patients with gliomas and also characterize serial imaging. Kinetic modeling of serial data has most importantly shown evidence of aberrant metabolism in patients with progressive glioblastoma. Additionally, earlier studies in patients with prostate cancer have indicated potential clinical relevance, based on the elevated ratio of [1-13C] lactate to [1-13C]pyruvate in biopsy-proved disease.

Despite advances in the molecular characterization of pediatric brain tumors, development of imaging biomarkers has remained elusive. Recent preclinical work evaluating [1-13C]pyruvate metabolism in human-derived orthotopic DIPG xenografts revealed that elevated levels of [1-13C]lactate could distinguish tumor from healthy brain stem tissue. These data, derived from a disease model recapitulating human histopathology, provided evidence that HP-[13C] imaging may offer relevant metabolic biomarkers of central nervous system tumors. Because DIPG lesions typically demonstrate only T2/FLAIR hyperintensity with little or no contrast enhancement in the weakly perfused environment of the brain stem, these results are promising for a variety of pediatric brain tumors with similarly challenging radiographic presentations. In the setting of recurrent disease, in which standard MR imaging may not have distinct characteristics to confirm active disease versus treatment effect, such biomarkers could provide considerable value. They are also particularly relevant in the context of monitoring the efficacy of targeted treatment, as indicated by recent investigations of treatment response to histone deacetylase inhibitors in preclinical models of glioblastoma.

The potential to identify tumor metabolism and biomarkers of treatment response combined with the preclinical and clinical support for HP-[1-13C]pyruvate provided the basis for investigating the use of HP-[1-13C]pyruvate in PNOC011, a “pilot study of safety and toxicity of acquiring HP-[13C] imaging in children with brain tumors” within the Pacific Pediatric Neuro-Oncology Consortium. The objectives of PNOC011 were to assess the safety and feasibility of HP-[13C] imaging in pediatric patients with brain tumors as a first step toward developing HP methodologies in this population. Herein, we describe our experience in PNOC011 using HP-[1-13C]pyruvate in a dose-escalation study evaluating pediatric patients with a variety of brain tumors.

**MATERIALS AND METHODS**

**Study Design**

PNOC011 was an open-label, limited Phase I trial using a standard 3 + 3 design to assess the safety of the investigational imaging agent HP-[1-13C]pyruvate across 2 dose levels in pediatric patients with brain tumors. Dose level 1 was 80% of the highest tolerated dose for adults (0.34 mL/kg). Dose level 2 was 100% of the highest tolerated dose for adults (0.43 mL/kg). The intent of the study was to enroll a minimum of 3 participants per dose level and a total of 6 participants at the highest tolerated dose level.

**Participant Population**

The single-center trial was conducted at the University of California, San Francisco, and designed to assess the safety and feasibility of HP-[1-13C]pyruvate given intravenously for dynamic HP-[13C] MR imaging. Participants were recruited from the pediatric neuro-oncology clinic at the University of California, San Francisco, according to enrollment guidelines stipulating that subjects be 3–18 years of age and previously diagnosed with a brain tumor. Key inclusion criteria were a Karnofsky Performance Status Scale or Lansky Play-Performance Scale score of ≥70; no severe, uncontrolled medical illness; not pregnant or breastfeeding; use of effective contraception; and ability to provide informed consent. Key exclusion criteria included an inability to follow study procedures and a history or evidence of cardiac dysfunction. Any participant who was undergoing active anticancer therapy or on another investigational trial at the time of enrollment on PNOC011 was discussed with and approved by the study chair (S.M.). All participants and families provided informed consent or assent, as applicable, before initiation of protocol interventions.

This study was approved by the University of California, San Francisco institutional review board and the FDA under Investigational New Drug No. 131057 (S.M.). The trial was registered on clinicaltrials.gov under NCT02947373.

**Study Assessments**

Before enrollment, participants underwent a complete neurologic examination, assessment of a performance score, evaluation of complete blood counts, liver function tests, and evaluation of electrolyte levels, as well as a baseline electrocardiogram. During and for 60 minutes after completion of the injection and imaging acquisition, the participant underwent continuous heart rate monitoring. Oxygen saturation and blood pressure were assessed every 15 minutes for a total of 60 minutes after completion of injection. An electrocardiogram was also repeated 60 minutes after the injection. Participants were contacted by the study team at 24 and 48 hours after completion of the injection to assess any toxicities related to HP-[1-13C]pyruvate.

During the injection and imaging acquisition, a minimum of 2 pediatric advanced life-support–certified providers were present to monitor any acute events related to study procedures (C.K., C.H., S.R., S.M.).

**Study End Points**

The primary end point of the study was safety based on the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. Adverse events and serious adverse events were reported from the time of enrollment to 48 hours post-injection. Dose-limiting toxicities were defined as any HP-[1-13C] pyruvate–related grade 2 or higher toxicity (excluding asymptomatic laboratory evaluations). Adverse events and serious adverse events were reviewed weekly by the study chair (S.M.) and the Pacific Pediatric Neuro-Oncology Consortium leadership (S.M., M.P.) per the Pacific Pediatric Neuro-Oncology Consortium.
standardized operating procedures for safety review of clinical trials. The University of California, San Francisco Data Monitoring and Safety Committee monitored the trial.

The secondary end point was image quality, which was assessed qualitatively on the basis of descriptive characteristics only.

**13C Hardware and Calibration**

All experiments were performed on a clinical 3T whole-body scanner (MR 750; GE Healthcare) equipped with 32-channel multi-nuclear imaging capability. Either an 8-channel bilateral paddle coil or a 32-channel head array coil with 13C hardware configuration was used for optimal 13C signal reception.18 Transmit radiofrequency power was calibrated on a head-shaped phantom containing unenriched ethylene glycol (anhydrous, 99.8% HOCH₂CH₂ OH; Sigma Aldrich).

**Sample Polarization and Quality Control**

Dynamic nuclear polarization of [1-13C]pyruvate was performed using a 5T Spinalab polarizer (GE Healthcare) designed for clinical research applications.9 To maintain an International Organization for Standardization 5 environment, pharmacists used an isolator (Getinge Group; Getinge 4-Glove Isolator Laminar Airflow, No. 2989; Getinge, France) and a clean bench laminar flow hood for the preparation of human [1-13C]pyruvate doses. Pharmacy kits filled with a mixture of 1.432-g [1-13C] pyruvic acid (Millipore Sigma) and a 25 mg electron paramagnetic agent (AH111501; GE Healthcare) were loaded into the Spinalab and polarized for at least 2.5 hours with 140-GHz microwave radiation at 5 T and 0.8 K. Following polarization, the pyruvate and trityl radical solution was rapidly dissolved in sterile water and passed through a filter under pressure to achieve a residual trityl concentration of <3 μM. This solution was then collected in a receiver vessel, neutralized, and diluted with a sodium hydroxide tris (hydroxymethyl) aminomethane/ethylenediaminetetraacetic acid buffer solution. An integrated quality control system rapidly measured the resulting pH, temperature, residual electron paramagnetic agent concentration, volume, pyruvate concentration, and polarization level. The solution passed through a terminal sterilization filter (Saint-Gobain PureFlo® D65R disc filter, 0.2 μm; Zempure) before being collected in a Medrad syringe (Bayer HealthCare).

The quality control criteria for pharmacist release of the sample were the following: 1) polarization, ±15%; 2) pyruvate concentration, 220–280 mM; 3) electron paramagnetic agent concentration, ≤3.0 μM; 4) pH, 5.0–9.0; 5) temperature, 25–37 °C; 6) volume, >38 ml; and 7) bubble point test on the sterilizing filter passed at 50 psi. The injected volume of HP-[1-13C] pyruvate was based on a dosage of 0.34 mL/kg (dose level 1, n = 3) or 0.43 mL/kg (dose level 2, n = 3). The dose was delivered at a rate of 1–3 ml/s, less than the 5 ml/s used for adults, followed by a 20-mL sterile saline flush at the same rate.

**Imaging Protocol**

Before imaging, a peripheral intravenous catheter was placed for administration of HP [1-13C]pyruvate. T2-weighted fast spin-echo images (TR/TE = 4000/60 ms, FOV = 26 cm, 192 × 256 matrix, 5-mm section thickness, and number of excitations = 2) acquired with the 1H body coil served as an anatomic reference for prescribing 13C sequences. A 1-mL standard containing 8 mol/L of 13C-urea was embedded in both 8- and 32-channel phased array receiver coils to provide an in vivo frequency reference for [1-13C]pyruvate: fpyruvate = furea + 270 Hz. On pharmacist approval of sample safety, participants were injected with HP [1-13C]pyruvate and imaged beginning 0–5 seconds after the saline flush by either dynamic 13C EPI or echo-planar spectroscopic imaging (EPSI).

The EPI sequence (TR/TE = 62.5 ms/21.7 ms, FOV = 24 × 24 cm2, 8 slices, 20 time points, 3-second temporal resolution, 60-second acquisition time) was acquired with 3.38–4.50 cm2 spatial resolution and offered whole-brain coverage (Online Table 1).19 By means of spectral-spatial radiofrequency pulses, individual [1-13C]pyruvate, [1-13C]lactate, and [13C]bicarbonate resonances were sequentially excited over interleaved acquisitions with flip angles αpyruvate/αlactate/αbicarbonate = 20°/30°/30°. In the case of EPSI (TR/TE = 130/6.1 ms, 24 time points, 3-second temporal resolution, 72-second acquisition time), single-section spectroscopic imaging data were acquired with a spatial resolution of 8 cm3 and flip angles of 10° for all metabolites (Online Table 1).20 Two participants were repositioned after study protocol injection and HP-13C imaging for a short 1H-MR imaging examination without gadolinium contrast using a 32-channel 1H coil (Nova Medical, Wilmington, Massachusetts). This examination included 3D T1-weighted inversion recovery echo-spoiled gradient-echo images (TR/TE/TI = 6652/2448/450 ms, resolution = 1.5 × 1 × 1 mm3, FOV = 25.6 cm, matrix = 256 × 256), and 3D T2-weighted FLAIR images (TR/TE/TI = 6250/138/1702 ms, resolution = 1.5 × 1 × 1 mm3, FOV = 25.6 cm, matrix = 256 × 256). This imaging was performed to obtain quality proton images to overlay the carbon data.

**Postprocessing of 13C Data**

Dynamic EPI and EPSI 13C data were processed according to previously described methods21 and postprocessed to enhance the signal.22 These data were then summed across time to display the total metabolite signal. The apparent total signal-to-noise ratio (aSNR) in the brain was computed by dividing the temporally summed metabolite signal, peak height values in the case of EPSI, by the SD of the noise outside the head.

**RESULTS**

A total of 10 pediatric participants (9 males; median age, 14 years; range, 10–17 years) were enrolled (Table 1 and Online Table 2). Two additional participants consented to participate in the study but did not enroll (one due to disease progression and not returning to University of California, San Francisco for follow-up and the other due to changing his mind about participation). Due to technical issues related to generating HP [1-13C]pyruvate (n = 3) or MR imaging scanner operability (n = 1), 4 participants consented and enrolled, but did not undergo HP-13C MR imaging or injection of HP [1-13C]pyruvate. Details of the remaining 6 participants who underwent HP-13C MR imaging with injection of HP [1-13C]pyruvate can be found in Online Table 2 (5 males; median age, 14 years; range, 10–17 years). Diagnoses included DIPG (n = 3), pineoblastoma (n = 1), medulloblastoma (n = 1), and adamantinomatous craniopharyngioma (n = 1). Of these 6 participants, 3 were on active therapy at the time of HP-13C imaging. Following injection of HP
[1-13C]pyruvate, there were no adverse events in any participant at dose levels 1 or 2 based on assessments by supervising personnel and electrocardiogram and vital sign monitoring.

Table 2 provides the quality control measurements recorded for each dissolution of HP [1-13C]pyruvate before injection, including the delivered dosage volume (16–36 mL) and concentration (230–242 mM), with the time to injection ranging from 53 to 75 seconds.

Dynamic HP-13C imaging was successfully performed on participants using both the imaging- and spectroscopy-based acquisition schemes. Individual scan parameters are reported along with aSNR values from normal brain in Online Table 1. On the basis of the maximum aSNR that was calculated in the brain for each examination after applying signal-enhancement postprocessing techniques, HP [1-13C]pyruvate (aSNR, 7.85 × 10^2), [1-13C]lactate (aSNR, 1.75 × 10^2 − 7.20 × 10^4), and [13C]bicarbonate (aSNR, 64 − 1.52 × 10^4) were detectable across all participants (Online Table 1). Incidentally, each of the EPSI datasets was acquired with the paddle receiver coils, which allowed relatively high aSNR based on their proximity to the head.

Figure 1 shows HP-13C EPI data from a 9-year-old male participant (P-01) with DIPG, which have been overlaid on FLAIR images that demonstrated a hyper- and hypointense T2 lesion, indicated by the yellow arrows. Temporally summed signal from 13C-labeled metabolites provided evidence that HP [1-13C]pyruvate was transported across the BBB and subsequently underwent conversion to both [1-13C]lactate and [13C]bicarbonate. On the basis of visual inspection, the [1-13C]lactate signal in this anatomic lesion displayed a slight elevation relative to the normal-appearing contralateral brain stem (Fig 1, middle row). The same region is highlighted by the signal ratio map of [1-13C]lactate to [1-13C]pyruvate, which is free from the receive profile of 13C hardware sensitivity (Fig 1, bottom row). At the time of study imaging, the patient was about 3 months from completion of radiation and undergoing therapy with convection-enhanced delivery with MTX110 (liquid panobinostat) coinfused with gadoxetidol. Most interesting, on visual review of contrast-enhanced MR imaging of tumor regions previously treated with convection-enhanced delivery, the area of elevated lactate had not been reached with prior treatments.

Figure 2 displays HP-13C EPSI spectra from a 12-year-old male participant (P-02) with DIPG who was undergoing therapy with trametinib and everolimus. These HP-13C spectra are shown in relation to a FLAIR image demonstrating a T2-hyperintense lesion. Temporally summed 13C spectra from a single section depict individual resonances of [1-13C]pyruvate, [1-13C]lactate, and [13C]bicarbonate (alised from 160.8 ppm) throughout the inferior brain stem (Fig 2A). Spectra from voxels corresponding with normal-appearing tissue (Fig 2B) and the lesion (Fig 2C) are annotated for metabolite reference. Due to the relatively large voxel size (8 cm3), some of the signal from Fig 2B is external to the brain, particularly in the case of [1-13C]alanine.

**Table 1: Participant demographics**

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Consented (n = 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median) (range) (yr)</td>
<td>14 (8–17)</td>
</tr>
<tr>
<td>Males (No.) (%)</td>
<td>10 (83)</td>
</tr>
<tr>
<td>Treatment (No. of patients)</td>
<td></td>
</tr>
<tr>
<td>Completed protocol therapy</td>
<td>6</td>
</tr>
<tr>
<td>Eligible, withdrawn*</td>
<td>6</td>
</tr>
<tr>
<td>Completed 13C injection (n = 6)</td>
<td></td>
</tr>
<tr>
<td>Age (median) (range) (yr)</td>
<td>14 (10–17)</td>
</tr>
<tr>
<td>Males (No.) (%)</td>
<td>5 (83)</td>
</tr>
<tr>
<td>Diagnosis (anatomic location) (No.) (%)</td>
<td></td>
</tr>
<tr>
<td>Diffuse intrinsic pontine glioma (pons)</td>
<td>3 (50)</td>
</tr>
<tr>
<td>Craniopharyngioma (suprasellar)</td>
<td>1 (77)</td>
</tr>
<tr>
<td>Medulloblastoma (posterior fossa)</td>
<td>1 (77)</td>
</tr>
<tr>
<td>Pineoblastoma (pineal gland)</td>
<td>1 (77)</td>
</tr>
<tr>
<td>Dose level (No. of patients)</td>
<td></td>
</tr>
<tr>
<td>Dose level 1</td>
<td>3</td>
</tr>
<tr>
<td>Dose level 2</td>
<td>3</td>
</tr>
<tr>
<td>Safety (No. of events)</td>
<td>0</td>
</tr>
<tr>
<td>Dose level toxicity</td>
<td>0</td>
</tr>
<tr>
<td>Adverse events</td>
<td>0</td>
</tr>
</tbody>
</table>

*Withdrawn due to the following technical issue with MR imaging scanner (n = 1) or generating HP [1-13C]pyruvate (n = 3); change in participant choice to participate (n = 1); or disease progression before participation and participant did not return to University of California, San Francisco for follow-up treatment (n = 1).

**Table 2: Quality control for HP-13C injections**

<table>
<thead>
<tr>
<th>Participant ID</th>
<th>EPA Conc. ([1-13C]Pyruvate Conc.)</th>
<th>Volume Injected</th>
<th>Polarization (%)</th>
<th>Temp. (°C)</th>
<th>pH</th>
<th>Time to Injection (sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P-01</td>
<td>1.6 (mM)</td>
<td>230 mL</td>
<td>23.0</td>
<td>44.0</td>
<td>34.6</td>
<td>7.7</td>
</tr>
<tr>
<td>P-02</td>
<td>0.6 (mM)</td>
<td>232 mL</td>
<td>21.8</td>
<td>42.5</td>
<td>31.9</td>
<td>7.6</td>
</tr>
<tr>
<td>P-03</td>
<td>0.5 (mM)</td>
<td>235 mL</td>
<td>16.0</td>
<td>38.8</td>
<td>31.0</td>
<td>7.7</td>
</tr>
<tr>
<td>P-04</td>
<td>0.3 (mM)</td>
<td>230 mL</td>
<td>36.0</td>
<td>38.1</td>
<td>30.7</td>
<td>7.7</td>
</tr>
<tr>
<td>P-05</td>
<td>0.5 (mM)</td>
<td>231 mL</td>
<td>20.8</td>
<td>43.9</td>
<td>32.1</td>
<td>7.6</td>
</tr>
<tr>
<td>P-06</td>
<td>1.4 (mM)</td>
<td>242 mL</td>
<td>22.2</td>
<td>33.6</td>
<td>30.9</td>
<td>7.5</td>
</tr>
</tbody>
</table>

Note: EPA indicates electron paramagnetic agent; Conc., concentration; Temp., temperature.

**DISCUSSION**

Pediatric central nervous system tumors have historically presented challenges to radiographic interpretation of disease status on standard MR imaging, thereby prompting the exploration of alternative imaging strategies. Furthermore, current standard imaging frequently fails to adequately identify response or early treatment failure, particularly in the setting of developmental therapeutics, such as immunotherapy. PNOC011 demonstrated the tolerability of dynamic HP-13C metabolic imaging in pediatric participants with DIPG and other central nervous system tumors, while characterizing population-specific features of HP data. Injections of HP [1-13C]pyruvate were well-tolerated by all 6 participants without any reports of related adverse events. Based on the tolerance of HP [1-13C]pyruvate and the ability to detect conversion to downstream metabolites in real time, there is evidence that HP-13C techniques may inform about metabolism relevant to investigating pediatric DIPG and other brain malignancies.
Demonstrating the preliminary safety profile of HP-13Ci imaging in pediatric patients with a variety of CNS tumors represents a considerable advance with regard to translating this methodology to children. Within this population, the safety evaluation of HP [1-13C]pyruvate is of fundamental importance, and the experience thus far from the current study has matched the tolerability shown in adult brain studies. In addition to the record of safety, this study was able to provide evidence that HP-13Ci imaging can capture metabolically relevant data. As reported in adults, HP [1-13C]pyruvate displayed transport across the BBB and subsequent conversion to [1-13C]lactate and [13C]bicarbonate over experimental time scales of approximately 60–72 seconds. Given the quality of these data, as measured by aSNR, HP-13Ci imaging appears to hold promise for investigating aberrant metabolism in pediatric brain tumors.

Several features of pediatric HP-13Ci imaging that were characterized in this study will inform the design of future clinical trials. Notably, children demonstrated more rapid delivery of HP [1-13C]pyruvate to the brain following injection compared with adults, which is supported by the literature on their circulatory systems and may also reflect higher monocarboxylate transporter activity. This result has implications for HP-13Ci acquisitions because the kinetic modeling of [1-13C]pyruvate metabolism requires that the inflow of [1-13C]pyruvate be adequately sampled by imaging to quantify dynamic conversion. Thus, acquisitions should commence immediately following the completion of the injection. With respect to imaging of DIPG, the brain stem presented unique challenges because of its deep location in the head, which limited the detectability of 13C signal by the receiver hardware. Freedom in positioning the paddle 13C receivers helped reduce this issue by maximizing the proximity to the anatomic lesion; however, other pediatric indications may benefit from custom-designed detector arrays that better conform to the surface of the head. While the spatial resolution was relatively low in this study (3.38–8 cm2), variable resolution acquisition strategies and maintaining a short time to injection through quality control practices should greatly improve this issue.

One key limitation of this study was that only 3 participants were injected at the highest dose level. The initial study intent was to enroll 6 participants at the highest tolerated dose to most accurately assess toxicity of this novel imaging technology in children and as per standard 3 + 3 statistical design. The failure to sufficiently enroll patients was largely due to the following: 1) limitations in enrolling pediatric patients who did not require anesthesia for brain imaging, 2) technical challenges that led to the failure of MR imaging or HP-13Ci injection (4 of 10 patients), and 3) coordinating MR research imaging with other standard-of-care imaging in an effort to limit the impact and stress on pediatric patients. Unfortunately, anesthesia has been shown to alter HP acquisitions

![FIG 1. HP-13C imaging of DIPG. HP-13C EPI of a 9-year-old male participant (P-01) with DIPG following injection of HP [1-13C]pyruvate. Maps of the temporally summed signal from HP [1-13C]pyruvate and downstream metabolites [1-13C]lactate and [13C]bicarbonate are overlaid on 1H FLAIR images, along with the ratio of [1-13C]lactate to [1-13C]pyruvate, which removes the shading of 13C hardware sensitivity. Within the hyper- and hypointense T2 lesion indicated by the yellow arrows, there is a subtle increase in [1-13C]lactate signal relative to the normal-appearing contralateral brain stem. The ratio of [1-13C]lactate to [1-13C]pyruvate also demonstrates a local maximum in this anatomic lesion (yellow arrow). Pyr indicates pyruvate; Lac, lactate; Bicarb, bicarbonate; AU, arbitrary units.](image-url)
in preclinical models, so this may be a confound for applying this technique in the youngest populations. However, from a technical standpoint, injection-related failures can be overcome with evolving quality control procedures that preemptively address common issues.

Our group did identify particular challenges in the pediatric setting with regard to participation in nontherapeutic research studies because patients and families are already required to complete a large number of clinically relevant imaging and hospital visits. Such considerations in the pediatric setting must be taken into account for future imaging-based trials. One mechanism to potentially overcome these challenges would be to incorporate research imaging alongside interventional research studies. Another consideration for our trial is that we used weight-based volumes of metabolic contrast agent to facilitate consistent dosing across each dose level. While these volumes may display variability based on [1-13C]pyruvate mass, our study design remains aligned with what has been done in prior investigations of adults.

Because effective therapeutic options for many pediatric brain tumors are limited, radiation therapy and experimental treatments, such as immunotherapy, frequently become standard-of-care options. As molecular characterization for pediatric brain tumors evolves and more individually tailored therapies become available in the future, pediatric neuro-oncology will need to advance reliable imaging markers for evaluating response and resistance to treatment. From the results obtained in PNOC011, HP-13C imaging may assist in developing imaging markers that reflect underlying brain metabolism and offer such insight.

CONCLUSIONS

The safety and tolerability of dynamic HP-13C MR imaging with intravenously injected HP [1-13C]pyruvate in 6 pediatric patients with CNS tumors are very promising. Future studies with larger populations and options to incorporate HP-13C MR imaging alongside interventional studies will more comprehensively inform on the utility of HP-13C imaging for identifying imaging biomarkers.

ACKNOWLEDGMENTS

We thank all the children and their families for their participation. We also thank the entire Pacific Pediatric Neuro-Oncology Consortium operation team for their support of the development and conduct of the study.

Disclosures: Adam W. Autry—RELATED: Grant National Institutes of Health, Kure It-UCSF Grant for Unfunded Cancer Research, Comments: National Institutes of Health grant P41 EB0341598.

Kure It-UCSF Grant for Unfunded Cancer Research, Other: National Institutes of Health grant P41 EB0341598, Comments: T32 Training Fellowship T32 CA151022.

Cassie Kline—UNRELATED: Grants/Grants Pending: Cannonball Kids cancer foundation, Frank A. Campini Foundation, National Institutes of Health KL2 Scholars Program.

Hsin-Yu Chen—RELATED: Grant: National Institutes of Health, Kure It-UCSF Grant for Unfunded Cancer Research, Comments: This study was supported by the Kure It-UCSF Grant for Underfunded Cancer Research (SAM) and the National Institutes of Health P41 EB0341598 grant.


Michael Prados—RELATED: Grant: Kure It-UCSF Grant for Unfunded Cancer Research and University of California, San Francisco Comprehensive Cancer Center, Comments: nonprofit philanthropic group.

University of California, San Francisco Cancer Center: supplement grant (parent grant from the National Cancer Institute).

Sabine Mueller—RELATED: Grant: Kure It-UCSF Grant for Unfunded Cancer Research, Comments: research grant to support the clinical trial. The foundation had no impact on the design or analysis.

Duan Xu—RELATED: Grant: National Institutes of Health P41 EB0341598, Comments: money paid to the institution.

REFERENCES

